Impaired brain insulin signalling in Parkinson's disease
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: Brain insulin resistance (i.e., decreased insulin/insulin‐like growth factor‐1 [IGF‐1] signalling) may play a role in the pathophysiology of Parkinson's disease (PD), and several anti‐diabetic drugs have entred clinical development to evaluate their potential disease‐modifying properties in PD. A measure of insulin resistance is the amount of the downstream messenger insulin receptor substrate‐1 that is phosphorylated at serine residues 312 (IRS‐1pS312) or 616 (IRS‐1pS616). We assessed IRS‐1pS312 and IRS‐1pS616 expression in post‐mortem brain tissue of PD patients and a preclinical rat model based on viral‐mediated expression of A53T mutated human α‐synuclein (AAV2/9‐h‐α‐synA53T). Methods: IRS‐1pS312 and IRS‐1pS616 staining intensity were determined by immunofluorescence in both neurons and glial cells in the substantia nigra pars compacta (SNc) and putamen of PD patients and controls without known brain disease. We further explored a possible relation between α‐synuclein aggregates and brain insulin resistance in PD patients. Both insulin resistance markers were also measured in the SNc and striatum of AAV2/9‐h‐α‐synA53T rats. Results: We found higher IRS‐1pS312 staining intensity in nigral dopaminergic neurons and a trend for higher IRS‐1pS312 staining intensity in putaminal neurons of PD patients. We observed no differences for IRS‐1pS616 staining intensity in neurons or IRS‐1pS312 staining intensity in glial cells. IRS‐1pS312 showed high co‐localisation within the core of nigral Lewy bodies. Like PD patients, AAV2/9‐h‐α‐synA53T rats showed higher IRS‐1pS312 staining intensity in the SNc and striatum than controls, whereas IRS‐1pS616 was not different between groups. Conclusions: Our results provide evidence for brain insulin resistance in PD and support the rationale for repurposing anti‐diabetic drugs for PD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“downstream messenger insulin receptor substrate-1 that is phosphorylated at serine residues 312 (IRS-1pS312) or 616 (IRS-1pS616).(4,5)”
BackgroundGoedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123 · cited 1×
“agonist has shown neuroprotective effects in the transgenic hα-synA53T mouse model of PD and in mice injected with preformed α-syn fibrils, via the prevention microglia-mediated astrocyte activation.(63)”
BackgroundAguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010
Positive and negative regulation of insulin signaling through IRS-1 phosphorylation
Gual, P., Le Marchand-Brustel, Y., & Tanti, J.-F. (2005) · Biochimie · doi:10.1016/j.biochi.2004.10.019 · Cited by 912
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“Subsequently, a randomised placebo-controlled study has shown smaller, yet significant, differences on Unified PD Rating Scale III Off scores.(16) Additional clinical trials with exenatide, lixisenatide, liraglutide”
BackgroundPathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 2×
“downstream messenger insulin receptor substrate-1 that is phosphorylated at serine residues 312 (IRS-1pS312) or 616 (IRS-1pS616).(4,5)”
BackgroundExenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · cited 1×
“For instance, the GLP-1 analogue exenatide has shown positive effects on motor outcomes and cognition in an open-label study of 45 PD patients.(14,15) Subsequently, a randomised placebo-controlled study has shown smaller, yet significant, differences on Unified PD Rating Scale III Off scores.”
Background
Cited by
Trial of Lixisenatide in Early Parkinson’s Disease
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312323 · Cited by 369
Self-citationKopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
Rhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
“Since phase III AD trials of drugs other than Aβ antibodies have failed, 10–12 as have phase III trials on disease modifying treatments for PD, 13–16 the wide-ranging search for new AD and PD treatments continues.”
Influential
Metadata
- Authors
- Bassil, F., Delamarre, A., Canron, M., Dutheil, N., Vital, A., Négrier‐Leibreich, M., Bezard, E., Fernagut, P., & Meissner, W. G.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2021-09-13
- Volume
- 48
- Issue
- 1
- Pages
- e12760-e12760
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- OpenAlex
- W3195130648
- Cited by
- 73
- References
- 11
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.